Royce Global Value Trust, Inc. (RGT)

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Royce Global Trust, Inc. (NYSE-RGT) (the "Fund") has declared an annual distribution of $0.19 per share on its Common Stock.  The distribution, optionally payable in additional shares of Common Stock, or in cash by specific stockholder election, is to be paid on December 24, 2025 to stockholders of record at the close of business on December 11, 2025 (ex-dividend on December 11, 2025).

A closed-end fund that invests in global equities using a disciplined value approach. Average weekly trading volume of approximately 65,001 shares.

A closed-end fund that invests in global equities using a disciplined value approach. Average weekly trading volume of approximately 69,409 shares.

A closed-end fund that invests in global equities using a disciplined value approach. Average weekly trading volume of approximately 63,386 shares.

NEW YORK , Sept. 2, 2025 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 98,655 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 07/31/25 NAV 14.14 MKT 12.12 AVERAGE ANNUAL TOTAL RETURN AS OF 07/31/25 NAV (%) MKT (%) One-Month* -0.63 0.71 Year to Date* 12.67 12.99 One-Year 11.42 8.02 Three-Year 11.50 10.64 Five-Year 8.60 6.47 10-Year 8.49 8.65 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions.

NEW YORK , July 30, 2025 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 64,166 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 06/30/25 NAV 14.23 MKT 12.03 AVERAGE ANNUAL TOTAL RETURN AS OF 06/30/25           NAV (%)       MKT (%) One-Month* 5.64 4.83 Year to Date* 13.39 12.20 One-Year 18.38 12.95 Three-Year 14.71 13.23 Five-Year 9.95 8.25 10-Year 8.16 8.10 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.

Royce Global Trust (RGT) offers unique global small-cap exposure in a closed-end fund wrapper. The fund trades at a deep discount, but it is no bargain, as this is a regular occurrence. One of the reasons for this is that the fund does not offer an attractive distribution policy, which is often a key feature of CEFs.

NEW YORK , April 24, 2025 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 94,690 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 03/31/25 NAV 12.30 MKT 10.50 AVERAGE ANNUAL TOTAL RETURN AS OF 03/31/25 NAV (%) MKT (%) One-Month* -2.30 -3.40 Year to Date* -1.99 -2.07 One-Year 1.76 2.55 Three-Year 1.75 -0.17 Five-Year 12.38 13.30 10-Year 7.11 6.98 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.

Strategic Expansion Paired with Over $1M in Annual Cost Savings from Operational Restructuring PERTH, Australia , April 23, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval.

NEW YORK , March 27, 2025 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 33,066 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience   CLOSING PRICES AS OF 02/28/25 NAV 12.59 MKT 10.87   AVERAGE ANNUAL TOTAL RETURN AS OF 02/28/25 NAV (%) MKT (%) One-Month* -0.79 -0.55 Year to Date* 0.32 1.38 One-Year 9.72 7.16 Three-Year 3.06 1.44 Five-Year 8.28 6.86 10-Year 7.18 7.16 *Not Annualized   Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.

PERTH, Australia , March 16, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment.

Advanced wound care market projected to exceed $15 billion globally by 2030 PERTH, Australia , Feb. 12, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care.

NEW YORK , Jan. 27, 2025 /PRNewswire/ --  A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 72,971 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience   CLOSING PRICES AS OF 12/31/24 NAV 12.55 MKT 10.72   AVERAGE ANNUAL TOTAL RETURN AS OF 12/31/24 NAV (%) MKT (%) One-Month* -5.05 -5.03 One-Year 11.80 14.81 Three-Year -1.78 -4.18 Five-Year 5.69 5.57 10-Year 7.40 7.21 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.

PERTH, Australia , Jan. 7, 2025 /PRNewswire/ -- Argent BioPharma (ASX:RGT) (OTCQB:RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology. The company announces the successful completion of a US$4,500,000 (before costs) capital raise (Placement) through the subscription of 5,625,000 Units, each priced at US$0.80 (~A$1.28).

PERTH, Australia , Jan. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology. The company announces the successful completion of a US$4,500,000 (before costs) capital raise (Placement) through the subscription of 5,625,000 Units, each priced at US$0.80 (~A$1.28).

NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Royce Global Trust, Inc. (NYSE-RGT) (the "Fund") has declared a year-end distribution of $0.47 per share on its Common Stock.  The distribution, optionally payable in additional shares of Common Stock, or in cash by specific stockholder election, is to be paid on December 23, 2024 to stockholders of record at the close of business on December 12, 2024 (ex-dividend on December 12, 2024).